GlassScriptPhysician profile
Giovanni Lupo
NPI 1255394060
$5,133.73
in general payments reported to CMS, 2019-2025
32 companies · $793 in 2025
The $793 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2021: $571 · 2022: $665 · 2023: $624 · 2024: $1,696 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $794.21 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Janssen Pharmaceuticals, INC | $397.75 | 2019 | |
| Genentech USA, INC. | $270.23 | 2019-2021 | |
| Incyte Corporation | $252.20 | 2023-2024 | Jakafi, Monjuvi |
| Glaxosmithkline, LLC. | $248.92 | 2022-2024 | Zejula |
| Otsuka America Pharmaceutical, INC. | $207.83 | 2024 | Rexulti |
| Janssen Biotech, INC. | $149.86 | 2025 | Carvykti, Rybrevant |
| Ipsen Biopharmaceuticals, INC | $127.30 | 2023 | Tazverik |
| Exelixis INC. | $125.53 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Reblozyl |
| Pharmaessentia USA Corporation | $125.00 | 2025 | Besremi |
| Pharmacosmos Therapeutics INC. | $125.00 | 2024 | Monoferric |
| Eusa Pharma (US) LLC | $124.88 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $124.55 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.46 | 2024 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $124.46 | 2024 | |
| Genmab U.S., INC. | $124.46 | 2024 | Epkinly |
| Emd Serono, INC. | $124.46 | 2024 | |
| Taiho Oncology, INC. | $124.46 | 2024 | |
| Celgene Corporation | $124.46 | 2021 | |
| Daiichi Sankyo INC. | $124.46 | 2025 | Enhertu |
| Gilead Sciences, INC. | $124.46 | 2024 | Trodelvy |
| Syndax Pharmaceuticals, INC. | $123.69 | 2025 | |
| Blueprint Medicines Corporation | $120.83 | 2024 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $120.65 | 2022 | |
| Eisai INC. | $120.65 | 2022 | |
| Genzyme Corporation | $119.67 | 2024 | |
| Seagen INC. | $114.30 | 2022 | |
| Lilly USA, LLC | $110.73 | 2022 | |
| Mylan Specialty L.P. | $74.56 | 2022 | |
| Neurocrine Biosciences, INC. | $20.25 | 2025 | |
| Sun Pharmaceutical Industries INC. | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giovanni Lupo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.